Deucravacitinib (BMS-986165), a Tyk2 inhibitor that binds to the JAK homology 2 (JH2) domain, has been approved for treating psoriasis [16] and reported to be effective in the treatment of systemic lupus erythematosus (SLE) [17]. This evidence concerns the gene TYK2 and systemic lupus erythematosus.